Genitourinary small cell malignancies: Prostate and bladder

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Small cell carcinoma is an aggressive malignancy often associated with dismal prognosis due to the presence of advanced disease. Small cell malignancies, initially described in the lung (small cell carcinoma of the lung), can occur in extrapulmonary sites, such as prostate (small cell carcinoma of the prostate) and bladder (small cell carcinoma of the bladder), with similar clinicopathologic outcomes. There has been a paradigm shift in the management of small cell carcinoma of the lung from initial surgical treatment to use of chemotherapy followed by local therapies. Such treatment modalities have been applied to small cell carcinoma of the prostate and the bladder, with promise in improving patient survival. Use of platinum-based combination chemotherapy followed by surgical resection and/or radiation offers the most benefit. Further investigation at the molecular level may offer targeted therapies earlier in the course of the disease.

Original languageEnglish (US)
Pages (from-to)479-488
Number of pages10
JournalFuture Oncology
Volume11
Issue number3
DOIs
StatePublished - Feb 1 2015

Fingerprint

Small Cell Carcinoma
Prostate
Urinary Bladder
Small Cell Lung Carcinoma
Neoplasms
Therapeutics
Combination Drug Therapy
Platinum
Radiation
Drug Therapy
Lung
Survival

Keywords

  • bladder cancer
  • chemotherapy
  • prostate cancer
  • radiotherapy
  • small cell carcinoma
  • surgery

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Genitourinary small cell malignancies : Prostate and bladder. / Shatagopam, Kashyap; Kaimakliotis, Hristos Z.; Cheng, Liang; Koch, Michael O.

In: Future Oncology, Vol. 11, No. 3, 01.02.2015, p. 479-488.

Research output: Contribution to journalReview article

@article{4745666dc4794b1e8073e6f22c4e298e,
title = "Genitourinary small cell malignancies: Prostate and bladder",
abstract = "Small cell carcinoma is an aggressive malignancy often associated with dismal prognosis due to the presence of advanced disease. Small cell malignancies, initially described in the lung (small cell carcinoma of the lung), can occur in extrapulmonary sites, such as prostate (small cell carcinoma of the prostate) and bladder (small cell carcinoma of the bladder), with similar clinicopathologic outcomes. There has been a paradigm shift in the management of small cell carcinoma of the lung from initial surgical treatment to use of chemotherapy followed by local therapies. Such treatment modalities have been applied to small cell carcinoma of the prostate and the bladder, with promise in improving patient survival. Use of platinum-based combination chemotherapy followed by surgical resection and/or radiation offers the most benefit. Further investigation at the molecular level may offer targeted therapies earlier in the course of the disease.",
keywords = "bladder cancer, chemotherapy, prostate cancer, radiotherapy, small cell carcinoma, surgery",
author = "Kashyap Shatagopam and Kaimakliotis, {Hristos Z.} and Liang Cheng and Koch, {Michael O.}",
year = "2015",
month = "2",
day = "1",
doi = "10.2217/fon.14.277",
language = "English (US)",
volume = "11",
pages = "479--488",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Genitourinary small cell malignancies

T2 - Prostate and bladder

AU - Shatagopam, Kashyap

AU - Kaimakliotis, Hristos Z.

AU - Cheng, Liang

AU - Koch, Michael O.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Small cell carcinoma is an aggressive malignancy often associated with dismal prognosis due to the presence of advanced disease. Small cell malignancies, initially described in the lung (small cell carcinoma of the lung), can occur in extrapulmonary sites, such as prostate (small cell carcinoma of the prostate) and bladder (small cell carcinoma of the bladder), with similar clinicopathologic outcomes. There has been a paradigm shift in the management of small cell carcinoma of the lung from initial surgical treatment to use of chemotherapy followed by local therapies. Such treatment modalities have been applied to small cell carcinoma of the prostate and the bladder, with promise in improving patient survival. Use of platinum-based combination chemotherapy followed by surgical resection and/or radiation offers the most benefit. Further investigation at the molecular level may offer targeted therapies earlier in the course of the disease.

AB - Small cell carcinoma is an aggressive malignancy often associated with dismal prognosis due to the presence of advanced disease. Small cell malignancies, initially described in the lung (small cell carcinoma of the lung), can occur in extrapulmonary sites, such as prostate (small cell carcinoma of the prostate) and bladder (small cell carcinoma of the bladder), with similar clinicopathologic outcomes. There has been a paradigm shift in the management of small cell carcinoma of the lung from initial surgical treatment to use of chemotherapy followed by local therapies. Such treatment modalities have been applied to small cell carcinoma of the prostate and the bladder, with promise in improving patient survival. Use of platinum-based combination chemotherapy followed by surgical resection and/or radiation offers the most benefit. Further investigation at the molecular level may offer targeted therapies earlier in the course of the disease.

KW - bladder cancer

KW - chemotherapy

KW - prostate cancer

KW - radiotherapy

KW - small cell carcinoma

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=84923100835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923100835&partnerID=8YFLogxK

U2 - 10.2217/fon.14.277

DO - 10.2217/fon.14.277

M3 - Review article

C2 - 25675127

AN - SCOPUS:84923100835

VL - 11

SP - 479

EP - 488

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 3

ER -